MA42543A - Arn épitope peptidiques concatémériques - Google Patents
Arn épitope peptidiques concatémériquesInfo
- Publication number
- MA42543A MA42543A MA042543A MA42543A MA42543A MA 42543 A MA42543 A MA 42543A MA 042543 A MA042543 A MA 042543A MA 42543 A MA42543 A MA 42543A MA 42543 A MA42543 A MA 42543A
- Authority
- MA
- Morocco
- Prior art keywords
- concatemeric
- peptidic epitope
- epitope rna
- rna
- peptidic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562199204P | 2015-07-30 | 2015-07-30 | |
US201562245145P | 2015-10-22 | 2015-10-22 | |
US201562247367P | 2015-10-28 | 2015-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42543A true MA42543A (fr) | 2018-06-06 |
Family
ID=57886863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042543A MA42543A (fr) | 2015-07-30 | 2016-07-29 | Arn épitope peptidiques concatémériques |
Country Status (5)
Country | Link |
---|---|
US (2) | US20190008938A1 (fr) |
EP (1) | EP3328394A4 (fr) |
HK (1) | HK1256498A1 (fr) |
MA (1) | MA42543A (fr) |
WO (1) | WO2017020026A1 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
EP3324979B1 (fr) * | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Vaccins contre une maladie infectieuse |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
CA3003090A1 (fr) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins anticancereux |
AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP4349405A3 (fr) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Vaccins contre le virus respiratoire |
WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
CA3002912A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins a base d'acide nucleique contre le virus varicelle-zona (vzv) |
EP3964200A1 (fr) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions et procédés permettant d'administrer des agents thérapeutiques |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
MA45051A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant la relaxine |
EP4166666A1 (fr) | 2016-09-14 | 2023-04-19 | ModernaTX, Inc. | Compositions d'arn à pureté élevée et leurs procédés de préparation |
EP3528821A4 (fr) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
AU2017347837A1 (en) * | 2016-10-26 | 2019-06-06 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
WO2018089851A2 (fr) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Vaccin antigrippal |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
US20190351039A1 (en) * | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
CN110505877A (zh) * | 2017-02-01 | 2019-11-26 | 摩登纳特斯有限公司 | Rna癌症疫苗 |
EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
WO2018170256A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus de l'herpès simplex |
WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
EP3609534A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin à large spectre contre le virus de la grippe |
WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
WO2018167320A1 (fr) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Vaccin à arn et inhibiteurs de points de contrôle immunitaires pour une thérapie anticancéreuse combinée |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
US11203629B2 (en) * | 2017-04-22 | 2021-12-21 | Immunomic Therapeutics, Inc. | LAMP constructs |
EP3638215A4 (fr) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Formulations d'arn |
KR20200027499A (ko) * | 2017-07-12 | 2020-03-12 | 노우스콤 아게 | 암 치료용 신생항원 백신 조성물 |
FI3652606T3 (fi) * | 2017-07-12 | 2023-03-16 | Nouscom Ag | Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
WO2019148101A1 (fr) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Vaccins à base d'arn contre le vrs |
WO2019227106A1 (fr) * | 2018-05-25 | 2019-11-28 | The Wistar Institute | Néo-antigènes spécifiques d'une tumeur et leurs méthodes d'utilisation |
CN113365639A (zh) * | 2018-06-27 | 2021-09-07 | 摩登纳特斯有限公司 | 个性化癌症疫苗表位选择 |
CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
WO2020097291A1 (fr) * | 2018-11-07 | 2020-05-14 | Modernatx, Inc. | Vaccins à arn contre le cancer |
CA3114265A1 (fr) * | 2018-11-15 | 2020-05-22 | Nouscom Ag | Selection de mutations de cancer pour la generation d'un vaccin personnalise contre le cancer |
KR20210127924A (ko) * | 2019-01-04 | 2021-10-25 | 레퍼토리 아임뮨 메디신스, 인크. | 고다양성 펩티드 라이브러리의 제조 및 단백질 폴딩의 촉진 방법 |
JOP20210186A1 (ar) * | 2019-01-10 | 2023-01-30 | Janssen Biotech Inc | مستضدات البروستاتا المستحدثة واستخداماتها |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用rnaポリメラーゼバリアント |
AU2020234003A1 (en) * | 2019-03-11 | 2021-11-11 | Evaxion Biotech A/S | Nucleic acid vaccination using neo-epitope encoding constructs |
WO2020190750A1 (fr) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Vaccins à base d'arn contre le vih |
US12018289B2 (en) | 2019-11-18 | 2024-06-25 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
WO2021123232A1 (fr) * | 2019-12-18 | 2021-06-24 | Evaxion Biotech Aps | Vaccination par acides nucléiques au moyen de constructions codant pour des néo-épitopes |
CA3174215A1 (fr) | 2020-04-22 | 2021-10-28 | Ugur Sahin | Vaccin contre un coronavirus |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
GB202017119D0 (en) * | 2020-10-28 | 2020-12-09 | Oxford Vacmedix Uk Ltd | Polypeptides for cancer treatment |
WO2022120560A1 (fr) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | Immunosuppresseur sous forme posologique d'arnm et son application dans la préparation d'un médicament pour le traitement de tumeurs |
JP2024506629A (ja) * | 2021-02-09 | 2024-02-14 | バージニア コモンウェルス ユニバーシティー | mini環状RNA治療薬及びワクチン、並びにそれらの使用方法 |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2023161350A1 (fr) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Administration nucléotidique d'une thérapie anticancéreuse |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
GB202216449D0 (en) | 2022-11-04 | 2022-12-21 | Io Biotech Aps | TGF-BETA1 vaccine |
WO2024102764A1 (fr) * | 2022-11-07 | 2024-05-16 | The Wistar Institute Of Anatomy And Biology | Compositions contenant des néo-antigènes et méthodes d'amélioration de la thérapie anti-pd1 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2569633B1 (fr) * | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur |
DK2714071T3 (da) * | 2011-05-24 | 2019-09-16 | Biontech Rna Pharmaceuticals Gmbh | Individualiserede vacciner mod cancer |
SG10201602456WA (en) | 2011-08-31 | 2016-04-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
RS63244B1 (sr) * | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
WO2016128060A1 (fr) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Prédiction des épitopes de lymphocytes t utiles pour la vaccination |
-
2016
- 2016-07-29 WO PCT/US2016/044918 patent/WO2017020026A1/fr active Application Filing
- 2016-07-29 MA MA042543A patent/MA42543A/fr unknown
- 2016-07-29 US US15/748,773 patent/US20190008938A1/en active Pending
- 2016-07-29 EP EP16831458.1A patent/EP3328394A4/fr active Pending
-
2018
- 2018-12-05 HK HK18115564.4A patent/HK1256498A1/zh unknown
-
2021
- 2021-12-17 US US17/554,182 patent/US20220152178A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2017020026A1 (fr) | 2017-02-02 |
US20190008938A1 (en) | 2019-01-10 |
EP3328394A4 (fr) | 2019-03-13 |
EP3328394A1 (fr) | 2018-06-06 |
US20220152178A1 (en) | 2022-05-19 |
HK1256498A1 (zh) | 2019-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42543A (fr) | Arn épitope peptidiques concatémériques | |
MA44479A (fr) | Arn transrepliquant | |
MA47680A (fr) | Arn thérapeutique | |
DK3393510T3 (da) | Zikavirusvaccine | |
DK3197453T3 (da) | Kimært protein | |
DK3107562T3 (da) | P97-ids-fusionsproteiner | |
DK3099791T3 (da) | Protein | |
DK3184642T3 (da) | Gærcelle | |
DK3099793T3 (da) | Protein | |
DK3359083T3 (da) | Tandbørste | |
GB201616904D0 (en) | Vaccine | |
NO3050465T3 (no) | Seating | |
DK3157561T3 (da) | Forbedrede alpha-v beta-8 antistoffer | |
DE112016001950A5 (de) | Sitzgruppe | |
FI20170119A (fi) | Istuin | |
ES2775740T8 (es) | Péptidos | |
UA36457S (uk) | Песарій кільцеподібний | |
UA33364S (uk) | Стілець | |
UA33259S (uk) | Стілець | |
FI11433U1 (fi) | Postilaatikko | |
UA32920S (uk) | Стілець | |
FI20165227A (fi) | Ohjattava vastakkain-pyörivä potkurijärjestely | |
UA31285S (uk) | Стілець | |
UA30915S (uk) | Стілець | |
GB201603029D0 (en) | Vaccine |